Fosaprepitant
| |||
| (IUPAC) ime | |||
|---|---|---|---|
| [3[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl] ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl5-oxo- 2H-1,2,4-triazol-1-yl]phosphonic acid | |||
| Klinički podaci | |||
| Identifikatori | |||
| CAS broj | 172673-20-0 265121-04-8 (dimeglumin) | ||
| ATC kod | A04AD12 | ||
| PubChem[1][2] | 219090 | ||
| Hemijski podaci | |||
| Formula | C23H22F7N4O6P | ||
| Mol. masa | 614.406 g/mol | ||
| SMILES | eMolekuli & PubHem | ||
| |||
| Farmakokinetički podaci | |||
| Bioraspoloživost | n/a | ||
| Vezivanje za proteine plazme | >95% (aprepitant) | ||
| Metabolizam | u aprepitant | ||
| Poluvreme eliminacije | 9 do 13 sati (aprepitant) | ||
| Farmakoinformacioni podaci | |||
| Licenca | |||
| Trudnoća | B(US) | ||
| Pravni status | ℞-only (SAD) | ||
| Način primene | Intravenozno | ||
Fosaprepitant (Emend injekcije (SAD), Ivemend (EU)) je antiemetički lek, koji se upotrebljava intravenozno. On je prolek aprepitanta.
Fosaprepitant je razvio Merk. On je odobren u SAD FDA 25. januara, 2008.[3] i EMA 11. januara iste godine.[4]
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ „Drugs.com, FDA Approves Emend (fosaprepitant dimeglumine) for Injection, Merck's New Intravenous Therapy, for Use in Combination with Other Antiemetics for Prevention of Nausea and Vomiting Caused by Chemotherapy”. Pristupljeno 15. 03. 2008.
- ↑ „European Public Assessment Report for Ivemend (from the EMEA website)”. Arhivirano iz originala na datum 2008-02-28. Pristupljeno 15. 03. 2008.
